Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT03301168 |
Date of registration:
|
29/09/2017 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
|
Scientific title:
|
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR aß+T Cells in Pediatric Patients Affected by Hematological Disorders |
Date of first enrolment:
|
April 2014 |
Target sample size:
|
120 |
Recruitment status: |
Active, not recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT03301168 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 1/Phase 2
|
|
Countries of recruitment
|
Italy
|
United States
| | | | | | |
Contacts
|
Name:
|
Bellicum Pharmaceuticals |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Bellicum Pharmaceuticals, Inc. |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|